Evidence map›Paper›PMID 37924426›Full record

SynthesisMycopathologia2023

Cladosporium halotolerans: Exploring an Unheeded Human Pathogen.

Harsimran Kaur, Parakriti Gupta, Haseen Ahmad, Shamanth A Shankarnarayan, Sonakshi Srivastava, Suneeta Sahu, T Karuna, Tarun Narang, Sunita Gupta, Anup Ghosh and 1 more

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Mycopathologia, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Harsimran Kaur *Mycology Division, Department of Medical Microbiology, PGIMER, Chandigarh, 160012, India.
Parakriti Gupta *Department of Microbiology, Government Medical College and Hospital, Chandigarh, India.
Haseen AhmadMycology Division, Department of Medical Microbiology, PGIMER, Chandigarh, 160012, India.
Shamanth A ShankarnarayanDepartment of Physics, Charlebois Lab, Edmonton, AB, Canada.
Sonakshi SrivastavaDepartment of Microbiology, AIIMS, Kalyani, West Bengal, India.
Suneeta SahuClinical Microbiology and Molecular Biology, Apollo Hospitals Bhubaneswar, Bhubaneswar, India.
T KarunaDepartment of Microbiology, AIIMS, Bhopal, Madhya Pradesh, India.
Tarun NarangDepartment of Dermatology, Venereology and Leprology, PGIMER, Chandigarh, Chandigarh, 160012, India.
Sunita GuptaMycology Division, Department of Medical Microbiology, PGIMER, Chandigarh, 160012, India.
Anup GhoshMycology Division, Department of Medical Microbiology, PGIMER, Chandigarh, 160012, India.
Shivaprakash M RudramurthyMycology Division, Department of Medical Microbiology, PGIMER, Chandigarh, 160012, India. mrshivprakash@yahoo.com.ORCID http://orcid.org/0000-0002-9097-9253
Post Graduate Institute of Medical Education and Research · INAll India Institute of Medical Sciences Bhopal · INAll India Institute of Medical Sciences Raipur · INApollo Hospitals · INGovernment Medical College and Hospital · IN

Funding

DST SERB EMR/2017/003448
6 · The paper itself

Abstract

backgroundCladosporium halotolerans is a saprobic fungus, rarely implicated in human infections. The identification is challenging due to non-specific phenotypic features.

objectiveTo decipher clinical spectrum, microbiological and susceptibility profile of clinical and environmental isolates of Cladosporium halotolerans.

methodAll the isolates identified as Cladosporium halotolerans deposited in National Culture Collection for Pathogenic Fungi (NCCPF), Postgraduate Institute of Medical Education and Research, Chandigarh, India were revived. Phenotypic and molecular characterization targeting internal transcribed spacer (ITS) region of ribosomal DNA, large subunit of ribosomal DNA (LSU; NL1 and NL4), actin (ACT) and beta-tubulin (TUB) was done. Scanning electron microscopy (SEM) was performed to determine any phenotypic variations. Antifungal susceptibility testing (AFST) was carried out for eight antifungal agents as per CLSI M38 Ed3 guidelines. We also performed systematic literature review of all the cases of Cladosporium halotolerans reported till date.

resultsA total of four isolates (clinical, n = 3; soil, n = 1) identified as Cladosporium halotolerans were included in the study. The clinical sites were skin, maxillary tissue and nail. All patients were apparently immunocompetent, and history of trauma was recorded in one patient. All patients improved on antifungal therapy. The cultures revealed growth of black mycelial fungus and microscopic examination demonstrated dematiaceous septate hyphae with erect conidiophores and conidia in branched acropetal chains. Based on molecular methods, all the four isolates were identified as C. halotolerans. SEM revealed no variation in length and width of the conidia, conidiophores, ramoconidium and hyphae among the isolates. All molecular targets, such as ITS region, LSU (partially sequenced), ACT and TUB were able to differentiate the isolates. Minimum inhibitory concentrations for antifungals were: triazoles (0.12-2 μg/ml), amphotericin B (4 μg/ml) and echinocandins (2-8 μg/ml).

conclusionWe report role of the rarely isolated dematiaceous fungus, C. halotolerans, in causing human infections. The study emphasizes the role of molecular methods in precisely identifying these species. Triazoles are more active against these black fungi compared to polyenes or echinocandins.

Indexed as

Antifungal AgentsFungiCladosporiumDNA, RibosomalEchinocandinsHumansMicroscopy, Electron, ScanningSpores, FungalTriazolesAntifungal AgentsDNA, RibosomalEchinocandinsTriazolesCladosporium halotoleransHuman pathogenMolecular identification

Identifiers

PMID37924426
OpenAlexW4388344267

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.